Group items tagged

Internal medicine patients are frequently prescribed potentially inappropriate medications (PIMs), but screening tools can detect clinically relevant PIMs, according to a study published online Oct. 8 in the Journal of Clinical Pharmacy and Therapeutics. Anne-Laure Blanc, Pharm.D., Ph.D., from Geneva University Hospitals in Switzerland, and colleagues compared two PIM-screening tools -- STOPP/START and PIM-Check -- in a general internal medicine ward. They also analyzed a random sample of 50 patients hospitalized in 2013, whose readmission within 30 days of discharge had been potentially preventable, and 50 sex-and age-matched patients who were not readmitted. The researchers found that across the whole ward population, PIM-Check and STOPP/START detected 1,348 and 537 PIMs, respectively, which was the equivalent of 13.5 and 5.4 PIMs per patient. PIM-Check had a substantially shorter screening time versus STOPP/START (four versus 10 minutes). Of the PIMs detected using PIM-Check and STOPP/START, the clinical pharmacist found 45 percent and 42 percent, respectively, to be clinically relevant to individual patients' cases. There were no significant differences in the rates of detected and clinically relevant PIMs between readmitted and nonreadmitted patients.

44th Annual Vascular and Endovascular Issues, Techniques, Horizons (VEITH) Symposium is organized by Cleveland Clinic and would be held during Nov 14 - 18, 2017 at New York Hilton Midtown, New York, United States of America. The 5-day event features rapid-fire presentations from world renowned vascular specialists with emphasis on the latest advances, changing concepts in diagnosis and management, pressing controversies and new techniques. Objectives : Upon completion of the VEITHsymposium, the participants will, after learning about a wide array of topics, be able to: * Explain the practical implications of clinical trial data on new technologies and techniques for endovascular repair of abdominal aortic aneurysm and thoracic aortic disease * Summarize the impact of data on therapeutic advances for stroke and carotid disease management * Compare the safety, efficacy, and therapeutic indications of pharmacologic agents to the management of vascular disease * Assess data on the latest state-of-the-art for the treatment of superficial femoral and tibial artery disease and describe potential implications for clinical care * Summarize recent data on treatment advances for venous disease and explain their clinical implications * Provide new information about the latest developments in hemodialysis access and vascular malformations and tumors